格列本脲与二甲双胍及其联合方案治疗妊娠期糖尿病的比较:一项随机对照研究
这项前瞻性随机对照研究将妊娠13–33周、饮食控制不佳的妊娠期糖尿病患者随机分配至格列本脲组或二甲双胍组,必要时加用另一药物或换用胰岛素。格列本脲组53例、二甲双胍组51例;两组血糖控制及母婴结局相当,二甲双胍组二线治疗成功率更高、最终需胰岛素者更少,两药联合可显著减少胰岛素需求。
要点
- 格列本脲组53例中18例(34%)治疗失败,二甲双胍组51例中15例(29%)治疗失败。
- 二甲双胍组二线治疗成功13/15(87%),高于格列本脲组9/18(50%)(P=0.03)。
- 格列本脲组最终需胰岛素9例(17%),二甲双胍组2例(4%)(P=0.03)。
核心结论
- 格列本脲与二甲双胍作为妊娠期糖尿病的口服治疗在血糖控制和不良反应方面相当。
- 两药联合方案高效且显著减少胰岛素需求,二甲双胍作为一线治疗可能优于格列本脲。
研究设计与样本
- 前瞻性随机对照研究,纳入妊娠13–33周、饮食控制后血糖不佳的妊娠期糖尿病患者。
- 随机分配至格列本脲组53例或二甲双胍组51例;未达理想血糖控制则加用另一药物,出现不良反应则换药,两者均失败则给予胰岛素。
- 主要结局为一线药物治疗后的治疗失败率及根据每日平均血糖图评估的血糖控制情况。
主要发现
- 格列本脲组失败18例(34%),其中因不良反应(低血糖)6例(11%)、血糖控制不佳12例(23%)。
- 二甲双胍组失败15例(29%),其中因不良反应(胃肠道)1例(2%)、血糖控制不佳14例(28%)。
- 二线治疗后成功率二甲双胍组13/15(87%)vs 格列本脲组9/18(50%)(P=0.03)。
- 格列本脲组最终胰岛素治疗9例(17%)vs 二甲双胍组2例(4%)(P=0.03)。
- 两药联合使需胰岛素患者从33例(32%)降至11例(11%)(P=0.0002);两组每日平均血糖及巨大儿、新生儿低血糖、电解质紊乱等母婴结局相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS: In this prospective randomized controlled study, we randomly assigned patients with GDM at 13-33 weeks gestation and whose blood glucose was poorly controlled by diet to receive either glyburide or metformin. If optimal glycemic control was not achieved, the other drug was added. If adverse effects occurred, the drug was replaced. If both failed, insulin was given. The primary outcomes were the rate of treatment failure and glycemic control after the first-line medication according to mean daily glucose charts. RESULTS: Glyburide was started in 53 patients and metformin in 51. In the glyburide group, the drug failed in 18 (34%) patients due to adverse effects (hypoglycemia) in 6 (11%) and lack of glycemic control in 12 (23%). In the metformin group, the drug failed in 15 (29%) patients, due to adverse effects (gastrointestinal) in 1 (2%) and lack of glycemic control in 14 (28%). Treatment success after second-line therapy was higher in the metformin group than in the glyburide group (13 of 15 [87%] vs. 9 of 18 [50%], respectively; P = 0.03). In the glyburide group, nine (17%) patients were eventually treated with insulin compared with two (4%) in the metformin group (P = 0.03). The combination of the drugs reduced the need for insulin from 33 (32%) to 11 (11%) patients (P = 0.0002). Mean daily blood glucose and other obstetrical and neonatal outcomes were comparable between groups, including macrosomia, neonatal hypoglycemia, and electrolyte imbalance. CONCLUSIONS: Glyburide and metformin are comparable oral treatments for GDM regarding glucose control and adverse effects. Their combination demonstrates a high efficacy rate with a significantly reduced need for insulin, with a possible advantage for metformin over glyburide as first-line therapy.
引用
- Nachum Z, Zafran N, Salim R, et al. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care. 2017. PMID: 28077460. doi:10.2337/dc16-2307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。